iCaReMe Global Registry
NCT03549754 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 35000
Last updated 2025-12-09
Summary
To provide real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes, Hypertension, Heart failure and/or Chronic kidney diseases
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-02-17
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
Countries
- Brazil
- Chile
- Côte d’Ivoire
- Hong Kong
- India
- Iraq
- Kazakhstan
- Kenya
- Malaysia
- Mexico
- Nigeria
- South Africa
- Taiwan
- Ukraine
- United Arab Emirates
Study Locations
More Related Trials
-
Metformin in Moderate and Severe Renal Failure (CKD 3-4): A Follow-up Study
NCT02848508 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
NCT05709444 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
NCT03036150 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus
NCT01574365 ·Status: TERMINATED ·Phase: PHASE2
-
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
NCT05374291 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Prospective Decision Impact Trial of KidneyIntelX
NCT04960514 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
NCT06140537 ·Status: RECRUITING ·Phase: PHASE4
-
A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria
NCT03118713 ·Status: TERMINATED ·Phase: PHASE4
-
Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study
NCT06929169 ·Status: RECRUITING ·Phase: PHASE2
-
Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease
NCT05373004 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Therapeutic Drug Use for CKD Patients
NCT05818995 ·Status: UNKNOWN
-
A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
NCT00461006 ·Status: COMPLETED ·Phase: PHASE2
-
Renal Impairment in Type 2 Diabetic Subjects
NCT00554450 ·Status: COMPLETED ·Phase: PHASE1
-
Metformin in Kidney Disease
NCT02252081 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2b Diabetic Kidney Disease Study
NCT04170543 ·Status: COMPLETED ·Phase: PHASE2
-
DIALYSIS-TIR Study
NCT06042153 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
TRENDY Follow-up: Study on Endothelial Function in Subjects With Type 2 Diabetes Mellitus
NCT00905528 ·Status: COMPLETED
-
DAPAgliflozin for Renal Protection in Heart Transplant Recipients
NCT05321706 ·Status: RECRUITING ·Phase: PHASE3
-
Diabetic Patients With End-Stage Renal Disease
NCT00435786 ·Status: COMPLETED
-
OPTIMISE-CKD Drug Utilization
NCT05932901 ·Status: COMPLETED
-
A Study Using the LMC Diabetes Registry to Learn More About Chronic Kidney Disease (CKD) in Canadian Patients With Type 2 Diabetes (T2D)
NCT04445181 ·Status: COMPLETED
-
Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4
NCT05033054 ·Status: COMPLETED
-
Educational Intervention to Increase Select Guideline-recommended Cardioprotective Medications in Patients With Diabetes
NCT04862858 ·Status: UNKNOWN ·Phase: NA
-
Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease
NCT06249932 ·Status: RECRUITING ·Phase: PHASE4
-
Irbesartan in Type 2 Diabetes
NCT00317915 ·Status: COMPLETED ·Phase: PHASE3